Cloud Computing In Pharmaceutical Industry Market Size Projected to Reach $71.5 billion by 2034 | 14.6%

According to Straits Research the global cloud computing in pharmaceutical market was valued at $20.97 billion in 2025 and is anticipated to increase from $24.03 billion in 2026 to $71.5 billion by 2034, registering a CAGR of 14.6% during the forecast period (2026–2034).

Cloud computing in the pharmaceutical industry refers to the use of cloud-based platforms and services to store, process, and analyze data, enhancing efficiency across drug development, manufacturing, and distribution. Pharmaceutical companies can accelerate research, clinical trials, regulatory compliance, and supply chain management by leveraging scalable computing power, real-time data access, and advanced analytics. Cloud technology enables secure collaboration, AI-driven drug discovery, and cost-effective data storage, improving innovation and operational efficiency.

Market Dynamics

Enhanced data management and analytics drive the global market

Cloud computing is revolutionizing clinical data management, allowing pharmaceutical companies to efficiently collect, store, and analyze vast amounts of data. Cloud-based Clinical Data Management Systems (CDMS) optimize data handling, ensuring greater accuracy, faster insights, and seamless regulatory compliance. This transformation accelerates drug development timelines and enhances research efficiency.

• For instance, the Veeva Vault Clinical Data Management Suite (CDMS) offers an integrated platform that combines Electronic Data Capture (EDC), data aggregation, and centralized data cleaning. By utilizing Veeva Vault CDMS, pharmaceutical companies can streamline clinical workflows, strengthen data integrity, and expedite study completion, ultimately facilitating faster and more reliable drug approvals.

With cloud-powered data management solutions, pharmaceutical firms can minimize operational complexities, enhance collaboration, and optimize research outcomes, driving innovation and efficiency in drug development.

Faster drug discovery process creates tremendous opportunities

With its vast storage capacity and high-speed processing power, cloud infrastructure is transforming drug discovery by enhancing data organization, resource allocation, and computational efficiency. Cloud technology enables real-time sharing of diverse data—such as lab results, imaging, and statistical analyses—improving collaboration, enhancing decision-making, and minimizing bottlenecks in the drug development process.

• For example, in 2025, AstraZeneca, a leading biopharmaceutical company, adopted cloud-based solutions to accelerate its R&D efforts. By integrating cloud computing, AstraZeneca streamlined workflows, improved data accessibility, and expedited drug formulation and testing. This strategic shift has allowed the company to bring new treatments to market faster, outperforming competitors that are still reliant on traditional systems.

By leveraging cloud infrastructure, pharmaceutical firms can boost productivity, reduce costs, and gain a competitive edge, making faster drug development a critical market opportunity.

Regional Analysis

North America is the dominant region in the global cloud computing market for the pharmaceutical industry, primarily because of its advanced technological infrastructure and the presence of major cloud services providers such as AWS, Microsoft Azure, and Google Cloud. These companies provide scalable, reliable, and secure cloud solutions that address the complex needs of pharmaceutical companies, including large-scale data management, research acceleration, and improved operational efficiency.

• For instance, in January 2025, Donald Trump revealed a USD 500 billion private sector investment in AI data centers as he engaged firms such as OpenAI, SoftBank, and Oracle. This move would require over 100,000 jobs and ensure the U.S. maintains its supremacy in AI technology, supporting pharmaceutical and other related sectors that demand high computing capabilities.